BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15230672)

  • 21. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
    Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
    Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis.
    Botros N; Pickover L; Das KM
    Gastroenterology; 2000 Apr; 118(4):654, 809. PubMed ID: 10777349
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
    Baglieri F; Scuderi G
    Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractory pyoderma gangrenosum treated with infliximab in an infant.
    Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
    Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
    Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
    Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ulcerative colitis with refractory pyoderma gangrenosum.
    Liu FC; Liu NT; Huang TY
    QJM; 2020 Aug; 113(8):567-568. PubMed ID: 32129869
    [No Abstract]   [Full Text] [Related]  

  • 29. Dermatologic manifestations of Crohn disease in children: response to infliximab.
    Kugathasan S; Miranda A; Nocton J; Drolet BA; Raasch C; Binion DG
    J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):150-4. PubMed ID: 12883301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
    Groleau PF; Grossberg AL; Gaspari AA
    Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ulcerative pyoderma gangrenosum in inflammatory bowel disease.
    Motta I; Perricone G
    Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):488. PubMed ID: 31070128
    [No Abstract]   [Full Text] [Related]  

  • 33. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.
    Teich N
    Tech Coloproctol; 2014 Oct; 18(10):965-6. PubMed ID: 24965074
    [No Abstract]   [Full Text] [Related]  

  • 34. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
    Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
    Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab as a treatment for recalcitrant pyoderma gangrenosum.
    Singh M; Andrew SM; Lear JT
    Clin Exp Dermatol; 2004 Mar; 29(2):196-7. PubMed ID: 14987282
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
    Duchini G; Itin P; Arnold A
    Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine.
    Futami H; Kodaira M; Furuta T; Hanai H; Kaneko E
    J Gastroenterol; 1998 Jun; 33(3):408-11. PubMed ID: 9658322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
    Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
    Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyoderma Gangrenosum With Ulcerative Colitis Successfully Treated With Ustekinumab.
    Piqueras-García J; Sahuquillo-Torralba AJ; Torres-Navarro I; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):776-778. PubMed ID: 31151671
    [No Abstract]   [Full Text] [Related]  

  • 40. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.